Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.35 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.35 |
| ▸ | PRKCH | P24723 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7959648 | 0.89 | SLC6A7 (0.46) | SLC6A7LRRK2BACE1USP30PRKCQ | |
| SCHEMBL7962016 | 0.88 | USP2 (0.37) | LRRK2BACE1USP30PRKCQMAP4K1 | |
| SCHEMBL7957828 | 0.88 | SLC6A7 (0.45) | SLC6A7LRRK2BACE1USP30 | |
| SCHEMBL2375582 | 0.79 | BACE1 (0.41) | LRRK2BACE1 | |
| SCHEMBL2375588 | 0.79 | BACE1 (0.41) | LRRK2BACE1 | |
| SCHEMBL7964219 | 0.78 | BACE1 (0.38) | LRRK2BACE1CYP1A2CYP3A4TP53 | |
| SCHEMBL7949771 | 0.78 | BACE1 (0.39) | LRRK2BACE1 | |
| SCHEMBL12246411 | 0.78 | BACE1 (0.39) | LRRK2BACE1 | |
| SCHEMBL1820029 | 0.78 | BACE1 (0.45) | BACE1 | |
| SCHEMBL1820031 | 0.78 | BACE1 (0.45) | BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921359-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| EP-2324032-B1 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS INC (US) | 2014-10-01 | — | — | EP | disclosed |
| US-8450308-B2 | Inhibitors of beta-secretase | VITAE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | VITAE PHARMACEUTICALS, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| WO-2010021680-A2 | INHIBITORS OF BETA-SECRETASE | VITAE PHARMACEUTICALS, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218192-A1 | Inhibitors Of Beta-Secretase | BACE1, BACE2, APP | SLC6A7 965/4885LRRK2 401/4885BACE1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.